Fig. 4: Post-hoc exploratory analysis of serum protein profiling. | Nature Medicine

Fig. 4: Post-hoc exploratory analysis of serum protein profiling.

From: A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial

Fig. 4

a,b, Differentially abundant proteins in serum from patients receiving rentosertib at 30 mg BID (a) and 60 mg QD (b) identified with a generalized linear model. c, Serum levels of COL1A1, FAP, FN1 and MMP10 decrease with rentosertib dose and time on treatment. n = 11 patients in placebo, n = 11 patients in 30 QD, n = 11 patients in 30 BID, n = 10 patients in 60 QD. d, The changes in serum levels of COL1A1, FAP, FN1 and MMP10 from baseline to week 12 are inversely correlated with change in FVC from baseline to week 12. n = 43 patients at each visit; P value calculated by Pearson correlation analysis. e,f, Reactome pathway enrichment for differentially abundant proteins in serum from patients receiving rentosertib at 30 mg BID (e) and 60 mg QD (f).

Back to article page